Apr 30th 2021

ONWARD Completes $32 Million Financing Round

Apr 09th 2021

Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response

More news



Wellington Partners
Life Sciences

A leading European Venture Capital firm investing in early- and growth-stage Life Science companies.



Therapeutics, Medtech, Diagnostics, Digital Health and Biotechnology.

Strong entrepreneurial teams with deep domain knowledge.

Disruptive, innovative tech addressing highly unmet medical needs and attractive markets.



Europe, selectively in the US, leading VC in Germany.

Seed to late-stage private companies, highly selected PIPE investments.

Ticket sizes from €2m up to €20m over the life of the investment.



Over €440m invested and available for Life Science investments, investing out of our 5th fund generation.

Committed to invest and monitor portfolio using a solid ESG framework.

Investment team with strong clinical, scientific and operational backgrounds.